Antiretroviral abacavir linked with cardiovascular events in REPRIEVE trial
MedPage Today highlights UC-led trial analysis
People with HIV who took the antiretroviral drug abacavir (Ziagen) had an increased risk of major adverse cardiovascular events (MACE), according to an exploratory analysis of the REPRIEVE trial presented by the University of Cincinnati's Carl Fichtenbaum, MD, at the International AIDS Conference.
MedPage Today highlighted the findings that past use of abacavir increased the risk of MACE by 50% and current use increased MACE risk by 42%.
"Hopefully, with newer antiretrovirals and longer-acting therapy, perhaps this will become less and less of a problem as we're able to shift away and use other things to control HIV replication," said Fichtenbaum, professor in the Division of Infectious Diseases in the UC College of Medicine.
"Since there are many other options available — certainly in high-income countries — I think we have to consider the fact that the most important thing is controlling HIV replication, but that where we can, it may be helpful to avoid the use of abacavir," Fichtenbaum continued.
Read the MedPage Today article.
U.S. Pharmacist also highlighted the research. Read the U.S. Pharmacist article.
Featured photo at top of illustration of cardiovascular system. Photo/magicmine/iStock.
Related Stories
What Is Public Health Nursing? Career path and whether it’s right for you
April 6, 2026
When nurses consider graduate school, many immediately think of becoming a nurse practitioner. But there is another advanced path that is growing in demand, one focused not on treating individual patients, but on improving the health of entire communities: public health nursing.
What is the 'cicada' COVID variant?
April 6, 2026
A formerly rare strain of COVID, BA.3.2, now is showing up in Ohio and 24 other states. Experts say so far it hasn't caused illness any more severe than other strains, but it might be somewhat more resistant to vaccines, as 91.7 WVXU News recently reported. Scientists have nicknamed the variant "cicada" due to its former low profile and current resurgence.
UC opens zebrafish research facility to study infertility
April 6, 2026
The University of Cincinnati is launching a state-of-the-art zebrafish research facility that scientists say could help explain how environmental toxins affect fertility, as WKRC-TV/Local 12 and WLWT-TV/Ch. 5 recently reported.